AASK COHORT STUDY

高血压性肾病通常会进展。非裔美国人协会的主要目标 肾脏病和高血压的研究)队列研究是前瞻性确定肾脏的病程 患有高血压的非裔美国人肾脏疾病进展的功能和危险因素 接受推荐的抗高血压治疗的患者。次要目标是确定 心血管疾病的发生并评估其危险因素。 AASK队列研究是一项前瞻性观察性研究，是AASK试验的延伸。这个 AASK试验测试了3种初始降压药物(雷米普利、美托洛尔)的效果 和氨氯地平)和2个水平的血压控制。在1,094名试验参与者中，约有650至 700名尚未达到终末期肾病(ESRD)的患者可能会参加队列研究。 要研究的风险因素包括环境、遗传、生理和社会经济变量。这个 原发肾脏结局是一种综合的临床结局，其定义为血肌酐、终末期肾病或 死亡。高血压的药物治疗，从血管紧张素转换酶抑制剂开始 雷米普利，提供给所有参与者。通过这种方式，这项研究直接控制了两个主要决定因素 肾脏疾病进展(高血压的治疗和肾脏保护性抗高血压药物的使用 药物)。队列研究的最短随访期为5年(总计9至12年， 包括AASK审判期间)。 归根结底，来自AASK队列研究的数据应该会增强我们对风险因素和 决定肾脏疾病进展的过程。这样的结果可能最终会导致新的 延缓或预防ESRD的策略。

Hypertensive kidney disease commonly progresses. The primary objective of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African-Americans with hypertensive kidney disease who receive recommended antihypertensive therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects of 3 medications used as initial antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control. Of the 1,094 trial participants, approximately 650 to 700 individuals who have not reached end stage renal disease (ESRD) will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socio-economic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medication). The minimum duration of follow-up in the Cohort Study is 5 years (total of 9 to 12 years, including the period of the AASK trial). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.